

**ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE
REDUCATASE R2 AND USES THEREOF IN COMBINATION THERAPIES
FOR THE TREATMENT OF CANCER**

ABSTRACT

Combination products comprising an antisense oligonucleotide against the gene encoding a mammalian ribonucleotide reductase R2 protein and one or more immunotherapeutic agents, such as cytokines, non-cytokine adjuvants, monoclonal antibodies and cancer vaccines. The combinations can further comprise one or more chemotherapeutic agents. Methods of treating cancer in a mammal using the combinations are also provided.